Clinical Trials Browser

Phase 2 × Triple Negative Breast Neoplasms × mirvetuximab soravtansine × Clear all

NCT03106077 2020-12-02

Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast Cancer

Phase 2 Completed

96 enrolled 8 charts

Triple Negative Breast Neoplasms